Publications by authors named "Alexander Kristian"

Claim this Profile
T
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.
Eivind Valen Egeland, Kotryna Seip, Eleni Skourti, Geir Frode Øy, Solveig J Pettersen, Alexander Kristian

Br J Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models.
Niels Böhnke, Bård Indrevoll, Stefanie Hammer, Alex Papple, Alexander Kristian

Eur J Nucl Med Mol Imaging· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.
Sabine Zitzmann-Kolbe, Alexander Kristian, Dieter Zopf, Claudia Kamfenkel, Oliver Politz

Mol Cancer Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model.
Jenny Karlsson, Urs B Hagemann, Véronique Cruciani, Christoph A Schatz, Derek Grant, Alexander Kristian

Cancers (Basel)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted Th-Conjugate Therapy in Mice.
Linda N Broer, Daan G Knapen, Frans V Suurs, Ingrid Moen, Danique Giesen, Alexander Kristian

J Nucl Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model.
Axel Berg-Larsen, Anne Mobergslien, Ingrid Moen, Gebregziabher Petros, Alexander Kristian

Front Med (Lausanne)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Stefanie Hammer, Urs B Hagemann, Sabine Zitzmann-Kolbe, Aasmund Larsen, Christine Ellingsen, Alexander Kristian

Clin Cancer Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
Katrine Wickstroem, Urs B Hagemann, Alexander Kristian, Christine Ellingsen, Anette Sommer

Int J Radiat Oncol Biol Phys· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
Katrine Wickstroem, Jenny Karlsson, Christine Ellingsen, Véronique Cruciani, Alexander Kristian

Pharmaceuticals (Basel)· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic Effect of a Mesothelin-Targeted Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models.
Katrine Wickstroem, Urs B Hagemann, Véronique Cruciani, Antje M Wengner, Alexander Kristian

J Nucl Med· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influx rate of F-fluoroaminosuberic acid reflects cystine/glutamate antiporter expression in tumour xenografts.
Kathinka E Pitman, Santosh R Alluri, Alexander Kristian, Eva-Katrine Aarnes, Heidi Lyng

Eur J Nucl Med Mol Imaging· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Urs B Hagemann, Christine Ellingsen, Joachim Schuhmacher, Alexander Kristian, Anne Mobergslien

Clin Cancer Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis